Patents by Inventor Ulf Brueggemeier

Ulf Brueggemeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Covalent PPARG inverse-agonists
    Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • Covalent PPARG inverse-agonists
    Publication number: 20240109850
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 4, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Knut EIS, Elisabeth POOK, Ulf BRÜGGEMEIER, Adelaide Clara F. A. DE LEMOS, Sven CHRISTIAN, Isabel Sophie JERCHEL-FURAU, Ulrike RAUH, Nico BRÄUER, Timo STELLFELD, Anders Roland FRIBERG, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Charlotte Christine KOPITZ, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE, Timothy A. LEWIS
  • INHIBITORS OF SHP2
    Publication number: 20230034584
    Abstract: The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 2, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Tibor SCHOMBER, Ulf BRÜGGEMEIER, Michael BECKER, Sona PIRKULIYEVA
  • INHIBITORS OF SHP2
    Publication number: 20210230300
    Abstract: The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 29, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulf BRÜGGEMEIER, Tibor SCHOMBER, Karoline DRÖBNER, David ENGEL, Michael BECKER
  • Substituted benzyl and phenylsulfonyl triazolones, and use thereof
    Patent number: 8859601
    Abstract: The present application relates to new, substituted benzyl-1,2,4-triazolones and phenylsulfonyl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: October 14, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulf Brüggemeier, Ingo Flamme, Chantal Fürstner, Joerg Keldenich, Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Truebel
  • Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
    Patent number: 8796324
    Abstract: The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: August 5, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulf Brüggemeier, Chantal Fürstner, Volker Geiss, Jörg Keldenich, Armin Kern, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel
  • ACYLGLYCEROL ACYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF
    Publication number: 20130089552
    Abstract: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 11, 2013
    Inventors: Stefan Golz, Ulf Brüggemeier, Bernhard Weingartner, Andreas Geerts
  • SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
    Publication number: 20130005704
    Abstract: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Application
    Filed: December 26, 2011
    Publication date: January 3, 2013
    Applicant: BAYER PHARMA AKTIENGESELLSHAFT
    Inventors: Heinrich Meier, Eckhard Bender, Ulf Brüggemeier, Ingo Flamme, Dagmar Karthaus, Peter Kolkhof, Daniel Meibom, Dirk Schneider, Verena Voehringer, Chantal Fürstner, Jörg Keldenich, Dieter Lang, Elisabeth Pook, Carsten Schmeck
  • Acylglycerol acyltransferase-like protein MGAT-X1 and uses thereof
    Patent number: 8343745
    Abstract: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: January 1, 2013
    Assignee: Bayer Pharma AG
    Inventors: Stefan Golz, Ulf Brüggemeier, Bernhard Weingartner, Andreas Geerts
  • SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF
    Publication number: 20120238607
    Abstract: The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 20, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulf BRÜGGEMEIER, Chantal FÜRSTNER, Volker GEISS, Joerg KELDENICH, Armin KERN, Martina DELBECK, Peter KOLKHOF, Axel KRETSCHMER, Elisabeth POOK, Carsten SCHMECK, Hubert TRÜBEL
  • Diagnostics and therapeutics for diseases associated with G-protein coupled receptor AdipoR1(AdipoR1)
    Patent number: 8252525
    Abstract: The invention provides a human AdipoR1 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR1 as well as pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: August 28, 2012
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
  • Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
    Patent number: 8202895
    Abstract: The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: June 19, 2012
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulf Brüggemeier, Chantal Fürstner, Volker Geiβ, Joerg Keldenich, Armin Kern, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel
  • TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY
    Publication number: 20120053218
    Abstract: The present application relates to novel substituted phenylalanine derivatives, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: March 9, 2010
    Publication date: March 1, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulf Brüggemeier, Chantal Fürstner, Volker Geiß, Joerg Keldenich, Armin Kern, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel
  • LTBP2 as a biomarker and diagnostic target
    Patent number: 8088584
    Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 3, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
  • Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
    Patent number: 8084481
    Abstract: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: December 27, 2011
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Heinrich Meier, Eckhard Bender, Ulf Brüggemeier, Ingo Flamme, Dagmar Karthaus, Peter Kolkhof, Daniel Meibom, Dirk Schneider, Verena Voehringer, Chantal Fürstner, Jörg Keldenich, Dieter Lang, Elisabeth Pook, Carsten Schmeck
  • Diagnostics and Therapeutics for Diseases Associated with G-Protein Coupled Receptor AdipoR2 (AdipoR2)
    Publication number: 20110136107
    Abstract: The invention provides human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 26, 2010
    Publication date: June 9, 2011
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: STEFAN GOLZ, ULF BRÜGGEMEIER, ANDREAS GEERTS
  • CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET
    Publication number: 20110111394
    Abstract: The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 4, 2007
    Publication date: May 12, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
  • ACYLGLYCEROL ACETYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF
    Publication number: 20110086013
    Abstract: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: August 31, 2010
    Publication date: April 14, 2011
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Stefan Golz, Ulf Brüggemeier, Bernhard Weingärtner, Andreas Geerts
  • USE OF LYSOSOMAL CARBOXYPEPTIDASE C (PRCP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET
    Publication number: 20110033844
    Abstract: The invention provides a human PRCP which is associated with the cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of PRCP as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 25, 2007
    Publication date: February 10, 2011
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Brüggemeier, Adreas Geerts
  • SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF
    Publication number: 20100261771
    Abstract: The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: March 18, 2010
    Publication date: October 14, 2010
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulf Brüggemeier, Chantal Fürstner, Volker Geiss, Joerg Keldenich, Armin Kern, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel